Drug intelligence / Profile preview

Suhuang Zhike

Development stage: Unknown
Lead developer: Beijing Haiyan Pharmaceutical
Administration: Oral

Overview

Suhuang Zhike is a Traditional Chinese Medicine (TCM) formulation primarily used for the treatment of cough variant asthma (CVA) and post-infectious cough. Developed by the China-Japan Friendship Hospital, it is composed of nine herbal and animal-derived ingredients, including Ephedra, Perilla leaf, and Cicada slough. The drug exerts its therapeutic effects through anti-inflammatory, antitussive, and bronchodilatory mechanisms, effectively reducing airway hyperresponsiveness and suppressing cough. It is widely prescribed in China as a standard treatment for wind-cough syndrome, which aligns with the clinical presentation of CVA.

Brand names: Suhuang Zhike CapsuleSuhuang Zhike Jiaonang
Other names: Suhuang Zhike

Targets

ADRB2 (β2)IL-5 (Interleukin 5)TNFA (Tumor necrosis factor alpha (soluble))IL-4 (Interleukin 4)

Beyond the preview

Go deeper on Suhuang Zhike.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Suhuang Zhike.

Explore the full profile